imatinib mesylate has been researched along with Orthopedic Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Y; Chen, X; Chen, Y; Guo, Y; Liu, C; Yang, W; Zhang, L; Zhu, X; Zou, Y | 1 |
| Cortes, JE; DeGutis, I; Gajavelli, S; Gambacorti-Passerini, C; Goldberg, SL; Hehlmann, R; Mauro, MJ; Michallet, M; Paquette, RL; Sen, GP; Simonsson, B; Williams, LA; Zyczynski, T | 1 |
2 other study(ies) available for imatinib mesylate and Orthopedic Disorders
| Article | Year |
|---|---|
Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.
Topics: Abnormal Karyotype; Adolescent; Anorexia; Antineoplastic Agents; Child; Child, Preschool; China; Drug Evaluation; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Growth Disorders; Humans; Imatinib Mesylate; Infant; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Musculoskeletal Diseases; Progression-Free Survival; Protein Kinase Inhibitors; Remission Induction; Retrospective Studies; Treatment Outcome | 2021 |
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Topics: Aged; Antineoplastic Agents; Dasatinib; Disease Management; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Substitution; Europe; Female; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Molecular Targeted Therapy; Musculoskeletal Diseases; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Respiratory Tract Diseases; United States | 2019 |